Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Zachary A, Reuben, Alexandre, Amaria, Rodabe N, Wargo, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518/
https://www.ncbi.nlm.nih.gov/pubmed/25941608
http://dx.doi.org/10.4161/21624011.2014.954956
_version_ 1782352492553568256
author Cooper, Zachary A
Reuben, Alexandre
Amaria, Rodabe N
Wargo, Jennifer A
author_facet Cooper, Zachary A
Reuben, Alexandre
Amaria, Rodabe N
Wargo, Jennifer A
author_sort Cooper, Zachary A
collection PubMed
description Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequence of therapy.
format Online
Article
Text
id pubmed-4292518
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-42925182015-12-08 Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma Cooper, Zachary A Reuben, Alexandre Amaria, Rodabe N Wargo, Jennifer A Oncoimmunology Author's View Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from patients on trial, however important questions remain regarding toxicity, optimal timing and sequence of therapy. Taylor & Francis 2014-12-08 /pmc/articles/PMC4292518/ /pubmed/25941608 http://dx.doi.org/10.4161/21624011.2014.954956 Text en © 2014 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Cooper, Zachary A
Reuben, Alexandre
Amaria, Rodabe N
Wargo, Jennifer A
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title_full Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title_fullStr Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title_full_unstemmed Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title_short Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
title_sort evidence of synergy with combined braf-targeted therapy and immune checkpoint blockade for metastatic melanoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518/
https://www.ncbi.nlm.nih.gov/pubmed/25941608
http://dx.doi.org/10.4161/21624011.2014.954956
work_keys_str_mv AT cooperzacharya evidenceofsynergywithcombinedbraftargetedtherapyandimmunecheckpointblockadeformetastaticmelanoma
AT reubenalexandre evidenceofsynergywithcombinedbraftargetedtherapyandimmunecheckpointblockadeformetastaticmelanoma
AT amariarodaben evidenceofsynergywithcombinedbraftargetedtherapyandimmunecheckpointblockadeformetastaticmelanoma
AT wargojennifera evidenceofsynergywithcombinedbraftargetedtherapyandimmunecheckpointblockadeformetastaticmelanoma

Ejemplares similares